Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Microginin Synthetase - Gene Cluster and Application in Biocombinatorics

19.10.2012
<strong>Technology</strong><br>

The complete DNA sequence of the gene cluster coding for the microginin synthetase of the cyanobacterium Microcystis aeruginosa has been identified and sequenced for the first time. The microginin synthetase is a large multi-enzyme complex which catalyzes the microginin, a small linear lipopeptide belonging to the group of non-ribosomal synthesized peptides. <br><br> Microginins are synthesized by various species of cyanobacteria (“blue-green algae”) in diverse structure variants. Mircroginins represent an interesting group of unusual peptides in view of medical application as they are known to have inhibitory effects on the Angiotensin-Converting- Enzyme (ACE). Thus, microginins are potential ACE-inhibitors and represent important drug candidates to treat hypertension and associated diseases such as chronic heart failure and diabetic nephropathy.<br><br>

The new identified DNA-sequence of the microginin synthetase gene cluster can be used to identify homologue gene cluster in other cyanobacteria spe-cies and as a matter of fact for the detection of new microginin variants or microginin-like structures. Further on, novel microginin variants can be gen-erated by gene biocombinatoric experiments (gene shuffling) with the objec-tive to optimize the ACE-inhibitory effect. <br><br> <b>Benefits:</b><ul> <li>10-30 % therapies of patients treated with currently available ACE-inhibitors are ineffective -> Novel or improved ACE-inhibitors to treat hypertension are needed</li> <li>Microginins are non-toxic and show ACE-inhibitory effects</li> <li>Easy and effective method to identify microginin-producing strains of cyanobacteria</li> <li>Easy method to generate novel non-natural microginins or microginin-like structures optimizing the ACE-inhibitory effect</li> </ul> <p><strong>IP Rights</strong><br> Patent granted in US, CH, DE, FR, GB, IE, LU, SE <br><br> <strong>Patent Owner</strong><br> Humboldt-Universität zu Berlin

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Dr. Dirk Dantz

info@technologieallianz.de | TechnologieAllianz e.V.
Further information:
http://www.technologieallianz.de/angebote.php?sort=sag&id=2860&lang=en
http://www.technologieallianz.de

More articles from Technology Offerings:

nachricht Synthesis of novel Myrtucommulone and Analogues
25.11.2013 | TechnologieAllianz e.V.

nachricht Transmission signal separation in radar systems for OFDM and multicarrier radar
22.11.2013 | TechnologieAllianz e.V.

All articles from Technology Offerings >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

BrainScaleS Conference: From Neurobiology to New Computer Architectures

25.09.2014 | Event News

17th European Health Forum Gastein: “Electing Health – The Europe We Want”

23.09.2014 | Event News

Future questions regarding data processing

22.09.2014 | Event News

 
Latest News

Engineers complete first comprehensive mesh-free numerical simulation of skeletal muscle tissue

01.10.2014 | Medical Engineering

All directions are not created equal for nanoscale heat sources

01.10.2014 | Power and Electrical Engineering

Long-acting insulin is safer, more effective for patients with Type 1 diabetes

01.10.2014 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>